ABSTRACT:
The present study was aimed to develop sustained release floating tablet containing lisinopril by wet granulation technique. HPMC K4 M and Carbopol 934 P were used to sustain the drug release. The results of micromeretic properties of granules showed good flow behavior. Tablet weight variation, friability and drug content were within the specified limits. Tablet hardness and thickness were satisfactory. The tablets were hydrated gradually reaching a plateau after 8 h. The floating lag time varied from 22.9 - 68.6 seconds depending on polymer type and concentration. The in vitro drug release profile of tablets containing crosprovidone at its higher level and HPMC alone showed more than 50% of cumulative percentage drug release at the end of first 4 h of the dissolution study. However, from these tablets, at the end of 8 h the cumulative percentage drug release was found to be 71.03±4.975%. Formulations F11 containing HPMC K4M and Carbopol 934 and higher level of Croscarmellose sodium showed a higher percentage of drug release (79.15±2.688%) when compared to the other formulations. The developed floating system enhanced the retention time and prolonged the drug release in 0.1 N HCl (pH 1.2), which could improve the local availability of the drug.
Cite this article:
Akash Tandon, Pankaj Kumar Jangra. Formulation and in vitro Evaluation of Lisinopril floating Gastroretentive Tablets. Research J. Pharm. and Tech. 2021; 14(1):207-213. doi: 10.5958/0974-360X.2021.00036.6
Cite(Electronic):
Akash Tandon, Pankaj Kumar Jangra. Formulation and in vitro Evaluation of Lisinopril floating Gastroretentive Tablets. Research J. Pharm. and Tech. 2021; 14(1):207-213. doi: 10.5958/0974-360X.2021.00036.6 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-1-36
REFERENCES:
1. Shivakumar HG, Gauda VD. Floating control drug delivery systems for prolonging gastric residence. Indian J. Pharm. Educ. Res. 2004; 38: 172-179.
2. Awasthi R, Pawar V, Kulkarni GT. Floating microparticulate systems: An approach to increase gastric retention. Indian J Pharm. 2010;1(1):17-26.
3. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems. Drug Delivery 2011; 18:97–110.
4. Akala EO. Oral controlled release solid dosage forms. In: Jasti BR, Ghosh TK, eds. Theory and practice of contemporary pharmaceutics. 2nd ed. Florida: CRC Press, 2010; 333–66.
5. Siegel RA, Rathbone MJ. Overview of controlled release mechanisms. In: Siepmann J, ed. undamentals and applications of controlled release drug delivery, advances in delivery science and technology. Controlled Release Society. Netherlands: Springer, 2012; 19–43
6. Chien YW. Novel drug delivery systems. USA: Informa, Healthcare Inc. 2009.
7. Awasthi R, T Kulkarni G. Development of novel gastroretentive floating particulate drug delivery system of gliclazide. Current Drug Delivery. 2012;9(5):437-51.
8. Davis SS. Formulation strategies for absorption window. Drug. Discov. Today. 2005; 10: 249-257.
9. Gnanaprakash K, Shekhar KB, Chetty C. A review on floating drug delivery system of H2 receptors. Research Journal of Pharmacy and Technology. 2011;4(4):502-509.
10. Senthil SP, Sreeja MK, Vincent J, Singh MK. Formulation and In vitro Evaluation of Gastroretentive Floating Tablets of Ivabradine Hydrochloride using Different Polymers. Research Journal of Pharmacy and Technology. 2014;7(9):973-975.
11. Suradkar P, Mishra R, Nandgude T. Overview on Trends in Development of Gastroretentive Drug Delivery System. Research Journal of Pharmacy and Technology. 2019;12(11):5633-5640.
12. Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr. Opin. Pharmacol. 2006a: 501-508.
13. Awasthi R, Kulkarni GT. Decades of research in drug targeting to the upper gastrointestinal tract using gastroretention technologies: where do we stand?. Drug Delivery. 2016;23(2):378-94.
14. Bukka R, Patel N, Nargund LV, Prakasam K. Formulation and evaluation of coated floating tablets of captopril. Research Journal of Pharmacy and Technology. 2012;5(7):992-996.
15. Friedman M, Klausner E, Lavy E. Gastroretentive controlled release pharmaceutical dosage forms. US Patent. 2004; 6: 685- 962.
16. Fell JT, Atyabi F, Sharma HL, Mohammad HAH. In vivo evaluation of a novel gastric retentive formulation based on ion exchange resins, Journal of Controlled Release. 1996; 42: 105-113.
17. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery systems. Expert Opinion on Drug Delivery 2006b; 3: 217-233.
18. Awasthi R, Kulkarni GT. Development and characterization of amoxicillin loaded floating microballoons for the treatment of Helicobacter pylori induced gastric ulcer. Asian Journal of Pharmaceutical Sciences. 2013;8(3):174-80.
19. Gopalakrishnan S, Chenthilnathan A. Formulation and in vitro evaluation of Aceclofenac oral floating tablets. Research Journal of Pharmacy and Technology. 2011;4(4):642-645.
20. Rao GK, Mandapalli PK, Manthri R, Reddy VP. Development and in vivo evaluation of gastroretentive delivery systems for cefuroxime axetil. Saudi Pharmaceutical Journal. 2013;21(1):53-9.
21. Arunkumar N, Rani C, Mohanraj KP. Formulation and in vitro evaluation of oral floating tablets of atorvastatin calcium. Research Journal of Pharmacy and Technology. 2008;1(4):492-495.
22. Nur AO, Zhang JS. Captopril floating and/or bioadhesive tablets: design and release kinetics. Drug Development and Industrial Pharmacy. 2000;26(9):965-969.